A Study of Axitinib in Advanced Carcinoid Tumors

Status Completed

Clinical Trial Summary

The main purpose of this study is to see whether Axitinib will help prolong the time that the patient's carcinoid tumors remain stable, and to examine their treatment response through testing. Researchers also want to find out if Axitinib is safe and tolerable.

Clinical Trial Description

This is a bi-institutional, prospective phase II, open-label study. The target population is comprised of adult patients with histologically confirmed unresectable or metastatic carcinoid tumors. Carcinoid tumors are defined as well to moderately differentiated neuroendocrine tumors of the digestive tract and lungs. Patients with metastatic carcinoid tumors of unknown primary as well as rare primaries (renal, ovarian, thymic, hepatic) will also be eligible. Patients will be drawn from two institutions Moffitt Cancer Center (MCC) and The University of California, San Francisco (UCSF). ;

Study Design

Related Conditions & MeSH terms

Carcinoid Tumor

Clinical Trial Details

NCT number	NCT01435122
Study type	Interventional
Source	H. Lee Moffitt Cancer Center and Research Institute
Contact
Status	Completed
Phase	Phase 2
Start date	October 25, 2011
Completion date	February 13, 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05636618` - Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors	Phase 1/Phase 2
Recruiting	`NCT04993261` - An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors	Early Phase 1
Recruiting	`NCT04907643` - Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes	N/A
Active, not recruiting	`NCT03375320` - Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors	Phase 3
Not yet recruiting	`NCT04039516` - Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy	Phase 2
Completed	`NCT00780663` - Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma	Phase 2
Completed	`NCT00804336` - Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors	Phase 1
Completed	`NCT03723499` - Endoscopic Treatment of Bronchial Carcinoid Tumors
Recruiting	`NCT04017104` - Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging
Recruiting	`NCT04028479` - The Registry of Oncology Outcomes Associated With Testing and Treatment
Completed	`NCT00328497` - A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors	Phase 2
Completed	`NCT02399215` - Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors	Phase 2
Terminated	`NCT03420521` - Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors	Phase 2
Active, not recruiting	`NCT05477576` - Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy	Phase 3
Not yet recruiting	`NCT02038738` - 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors	Phase 1/Phase 2
Completed	`NCT01024387` - AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors	Phase 2
Completed	`NCT00446082` - Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease	Phase 1
Active, not recruiting	`NCT05361668` - Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome	Phase 2
Completed	`NCT01466036` - Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors	Phase 2
Completed	`NCT01398306` - Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours.